Universal reference book for medicines
Name of the preparation: IMMUNOVAK-VP-4 (IMMUNOVAC-VP-4)

Active substance: nonappropriate

Type: Immunostimulating drug

Producer: NGO MIKROGEN (Russia)
Composition, form of production and packaging
Liofilizate for the preparation of solution for intranasal administration and for oral administration 1 dose
antigens of conditionally pathogenic microorganisms (mixture of water-soluble antigens of microbial cells Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli) 4 mg
1 dose - bottles (10) - packs of cardboard.
Description of the drug approved by the manufacturer for the printed edition of 2013.
Immunostimulating drug of bacterial origin. The mechanism of action of the drug is based on the activation of key effectors of congenital and adaptive immunity. The drug activates the phagocytic activity of macrophages, corrects the number and functional activity of the lymphocyte subpopulations (CD3, CEM, CD8, CD16, CD72), programs the proliferation and activation of CD4 T lymphocytes along the Th1 pathway, increases the production of IFNy and IFNct, corrects the synthesis of immunoglobulin isotypes aside decrease in IgE and increase in IgG, IgA, slgA. It causes the production of antibodies to 4 types of conditionally pathogenic microorganisms whose antigens are included in the preparation, as well as to other species (Streptococcus pneumoniae, Haemophilus influenzae, etc.) due to the presence of wide cross protective activity in the antigens used. The clinical effect is manifested in a decrease in the frequency of acute infections, reducing the duration of their course, reducing the severity of symptoms, as well as reducing the likelihood of exacerbation of chronic diseases, reducing the volume of medications taken.
Immunotherapy and immunoprophylaxis in children from 3 to 18 years and adults.
Children from 3 to 15 years:
- inflammatory diseases of the respiratory system (including chronic) 5-7 days after the beginning of the basic therapy, as well as during the preseason increase in the number of respiratory infections;
- prevention of respiratory infections in children who are often ill with ARI (more than 4 times a year), incl. children who have not previously visited institutions with organized children's groups (before entering the children's institutions - pre-school, schools);
- allergic diseases (bronchial asthma, obstructive bronchitis, atopic dermatitis, pollinosis) during remission on the background of basic therapy, preferably during the preseason rise in morbidity or immediately after relieving the aggravation against baseline therapy;
- Dysbacteriosis caused by a conditionally pathogenic microflora, with atopic dermatitis.
Children over 15 years and adults:
- chronic recurrent inflammatory diseases of respiratory organs in the acute stage 5-7 days after the beginning of basic therapy, during remission, as well as during the preseason increase in the number of respiratory infections;
- Allergic diseases (including bronchial asthma of mixed and infectious-allergic types, atopic dermatitis) during remission on the background of basic therapy or after relieving exacerbations on the background of basic therapy;
- prevention of respiratory infections in people who are often ill with ARI (more than 4 times a year), during the preseason rise in morbidity.
The drug is taken by a combined scheme intranasal, then inside. In the vial with the drug, 4 ml of a solvent (sodium chloride solution 0.9% for injection or boiled water) are introduced immediately into the syringe using a syringe at a temperature of 18-25 ° C and mixed. The dissolution time should not exceed 2 min. The dissolved preparation can be stored at a temperature of 2 ° to 8 ° C for 3 days and applied in the absence of turbidity.
The drug is administered intranasally with a medical pipette. When administered orally, the required volume of the drug is syringed and the contents of the syringe are transferred to a spoon. The drug is started with intranasal administration. Oral administration of the drug only occurs if intranasal administration of the patient is tolerated without significant reactions (an increase in body temperature of no more than 0.5 ° C, the absence of bronchospasm).
Scheme of drug administration for children over 3 years and adults
Procedure No. Interval between administrations Volume of solution administered Method of administration Note
children adults
1 1 drop 1 drop In one nasal passage
2 1 day 2 drops 2 drops 1 drop in each nasal passage
3 1 day 4 drops 4 drops 2 drops in each nasal passage
The interval between 3 and 4 injections 1-3 days
4 0.5 ml 2 ml Inside (through the mouth) At least 1 hour before taking the drug, the next meal at least 2 hours after taking the drug
5 3-5 days 2 ml 4 ml Inside (through the mouth)
6 3-5 days 4 ml 4 ml Inside (through the mouth)
7 3-5 days 4 ml 4 ml Inside (through the mouth)
8 3-5 days 4 ml 4 ml Inside (through the mouth)
9 3-5 days 4 ml 4 ml Inside (through the mouth)
10 3-5 days 4 ml 4 ml Inside (through the mouth)
11 3-5 days 4 ml 4 ml Inside (through the mouth)
When introducing the next dose for oral administration, it is necessary to take into account the intensity of the reaction to the previous oral administration of the drug. With subsequent administration, the dose of the drug is not increased with increasing body temperature by more than 0.5 ° C. At insufficiently expressed effect, if there is no response to 7-8 oral administration of the drug (if the temperature of the patient is not more than 37.5 ° C), it is recommended for adults to prolong the course of taking the drug with the same interval of administration in a dose of 4 ml. The maximum number of oral administrations for adults is 10; for children - 8.
Conducting repeated courses of immunotherapy - no earlier than 1 year if there are indications.
Perhaps a short (12-24 h) increase in body temperature to subfebrile values ​​(37.1-37.6 ° C), nasal congestion, cough, itchy skin. These adverse reactions pass independently for 1-2 days.
In the case of an increase in the body temperature of the patient to 38.5 ° C, keeping it 36 ​​hours after the administration of the drug at a level of 37.6 ° C and above, as well as in case of other side effects, the drug is stopped.
In patients with bronchial asthma, in rare cases, the aggravation of the underlying disease is possible. In the case of bronchospasm or an attack of bronchial asthma, an anti-ther- apy therapy is performed, and the question of the further administration of the drug is decided by an allergist.
Given the possibility of anaphylactic shock, in rare cases, especially sensitive persons, it is necessary to provide medical supervision of the vaccinated within 30 minutes after the administration of the drug. Venues of immunotherapy and immunoprophylaxis should be equipped with anti-shock therapy.
- mental illness during the period of exacerbation;
- collagenoses;
- tuberculosis process of any localization in the period of exacerbation;
- chronic diseases in the stage of decompensation;
- acute febrile conditions with hyperthermia (> 38 ° C);
- age up to 3 years (efficiency and safety not established);
- Pregnancy;
- the period of breastfeeding;
- Hypersensitivity to the components of the drug.
Contraindicated in pregnancy and lactation.
Contraindicated in children under 3 years of age (efficacy and safety not established).
Before use, it is necessary to make a visual inspection of the drug: the dissolved preparation must be a slightly yellowish slightly opalescent liquid without suspended particles.
The preparation is not suitable for use in vials with broken integrity, lack of marking, with a change in physical properties (color, transparency, etc.), expired shelf life, improper storage.
Immunotherapy with the drug is performed against the background of basic drug therapy. The cancellation of drugs of basic therapy is possible by the doctor's decision after the immunotherapy course Immunovac-VP-4.
Used in complex therapy with other drugs.
Compatible with antibiotics, antiviral, antifungal and antihistamine drugs, bronchodilators, corticosteroids, beta-adrenomimetics.
When carrying out immunotherapy or immunoprophylaxis, the use of other immunomodulators is not recommended 1 month before the start of the course and within 3 months after the course of immunotherapy or immunoprophylaxis with Immunovac-VP-4.
The drug is released by prescription.
The preparation is stored and transported at a temperature of 2 ° to 8 ° C. Transportation is allowed at a temperature of 9 ° to 25 ° C for a period not exceeding 10 days. Keep out of the reach of children.
Shelf life - 3 years. Do not use after expiry date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!